Francisco Cruz, MD
Endocrinology, Diabetes & Metabolism · Green Bay, WINPI 1184605339
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,663 of the $6,082 with a category attached, or 76.7%. 33 manufacturers reported payments, led by Medtronic at 30.0% of the total. Reporting peaked in 2019 at $4,382 and has fallen 84.3% since, to $688 in 2025.
Across 252 payments — averaging $24.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$675
- AstraZeneca$519
- Abbott$438
- Amgen$390
- Insulet Corporation$304
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$1,37523%
- Food & beverage$4,66377%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 16 | $1,827 |
| Novo Nordisk | 48 | $675 |
| AstraZeneca(2 entities) | 26 | $519 |
| Abbott | 20 | $438 |
| Amgen | 5 | $390 |
| Insulet Corporation | 17 | $304 |
| Valeritas, Inc. | 21 | $298 |
| Sanofi-aventis U.S. LLC | 20 | $264 |
| Amneal Pharmaceuticals LLC | 19 | $225 |
| Lilly USA, LLC | 13 | $174 |
| Boehringer Ingelheim | 5 | $164 |
| Tandem Diabetes Care, Inc. | 2 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $95 |
| Merck | 6 | $80 |
| Mannkind Corporation | 6 | $79 |
| AbbVie | 4 | $55 |
| Corcept Therapeutics | 2 | $48 |
| Eisai Inc. | 3 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| IBSA Pharma Inc. | 2 | $28 |
| Pfizer | 2 | $26 |
| Shire North American Group Inc | 1 | $20 |
| Bayer | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| BD | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Nalpropion Pharmaceuticals LLC | 1 | $15 |
| Companion Medical, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| UCB, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Embecta Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,375
- TEPEZZA$338
- Guardian Connect$220
- FARXIGA$125
- t:slim X2 Insulin Pump with Control-IQ$124
- Omnipod$118
- JARDIANCE$107
How this compares
$6,082 in reported general payments places this provider in the 85th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 22 | $423,066 |
| Teriparatide | 35 | $90,825 |
| OzempicSemaglutide | 23 | $38,365 |
| JardianceEmpagliflozin | 24 | $21,858 |
| TrulicityDulaglutide | 14 | $13,283 |
| XyostedTestosterone Enanthate | 15 | $9,428 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $7,941 |
| Testosterone | 16 | $3,501 |
| Cinacalcet Hcl | 48 | $2,834 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,419 |
| Hydrocortisone | 24 | $2,359 |
| SynthroidLevothyroxine Sodium | 30 | $2,322 |
| Levothyroxine Sodium | 175 | $1,543 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 12 | $1,051 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 12 | $1,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $675 | $38,36523 claims |
| Boehringer IngelheimJardiance | $164 | $21,85824 claims |
| Lilly USA, LLCTrulicity | $174 | $13,28314 claims |
| Antares Pharma, Inc.Xyosted | $14 | $9,42815 claims |
| AbbVieSynthroid | $55 | $2,32230 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $225 | $1,543175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Green Bay
- Jennifer CunninghamGreen Bay$15K
- Victor Compres MatosGreen Bay$558
- Gayle Kasdorf SchmelingGreen Bay$526
- Aron AdkinsEau Claire$349K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.